Cleaved-Plasminogen HC A short form (V98) Polyclonal Antibody

Rabbit Anti-Cleaved-Plasminogen HC A short form (V98) Polyclonal Antibody

Product Specifications

Background

The protein encoded by PLG is a secreted blood zymogen that is activated by proteolysis and converted to plasmin and angiostatin. Plasmin dissolves fibrin in blood clots and is an important protease in many other cellular processes while angiostatin inhibits angiogenesis. Defects in PLG are likely a cause of thrombophilia and ligneous conjunctivitis. Two transcript variants encoding different isoforms have been found for PLG.

CAS Number

9007-83-4

Product Name Alternative

PLG; Plasminogen

Gene ID

5340

Accession Number

P00747

Reactivity

Human, Mouse, Rat

Immunogen

Synthesized peptide derived from the N-terminal region of human Plasminogen HC A short form at AA range: 50-130

Clonality

Polyclonal

Tag

Plasminogen

Applications

WB, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

54kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

Cleaved-Plasminogen HC A short form (V98) Polyclonal Antibody detects endogenous levels of fragment of activated Plasminogen HC A short form protein resulting from cleavage adjacent to V98.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; ELISA 1:10000; Not yet tested in other applications.